Insider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Sells 27,912 Shares of Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) CEO Jay R. Luly sold 27,912 shares of the firm’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $45.16, for a total transaction of $1,260,505.92. Following the transaction, the chief executive officer now directly owns 819,810 shares in the company, valued at approximately $37,022,619.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Enanta Pharmaceuticals Stock Up 0.2 %

ENTA stock opened at $45.17 on Wednesday. The firm has a 50 day moving average of $49.73 and a 200 day moving average of $49.18. The stock has a market capitalization of $943.60 million, a PE ratio of -7.76 and a beta of 0.40. Enanta Pharmaceuticals, Inc. has a 52 week low of $37.59 and a 52 week high of $79.50.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last released its earnings results on Tuesday, February 7th. The biotechnology company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.13. The company had revenue of $23.60 million during the quarter, compared to analysts’ expectations of $22.48 million. Enanta Pharmaceuticals had a negative net margin of 146.93% and a negative return on equity of 36.59%. Enanta Pharmaceuticals’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same period last year, the business earned ($1.48) EPS. On average, equities research analysts expect that Enanta Pharmaceuticals, Inc. will post -7.36 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its stake in Enanta Pharmaceuticals by 2.9% during the 3rd quarter. BlackRock Inc. now owns 3,621,795 shares of the biotechnology company’s stock valued at $187,864,000 after acquiring an additional 103,059 shares during the period. Armistice Capital LLC lifted its stake in Enanta Pharmaceuticals by 0.3% during the 4th quarter. Armistice Capital LLC now owns 2,078,000 shares of the biotechnology company’s stock valued at $96,669,000 after acquiring an additional 6,000 shares during the period. State Street Corp lifted its stake in Enanta Pharmaceuticals by 29.9% during the 2nd quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company’s stock valued at $80,332,000 after acquiring an additional 390,842 shares during the period. Northern Trust Corp lifted its stake in Enanta Pharmaceuticals by 0.3% during the 2nd quarter. Northern Trust Corp now owns 931,291 shares of the biotechnology company’s stock valued at $44,022,000 after acquiring an additional 3,198 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Enanta Pharmaceuticals by 6.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 543,566 shares of the biotechnology company’s stock valued at $25,287,000 after acquiring an additional 33,688 shares during the period. 93.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on ENTA shares. Oppenheimer set a $50.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, November 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $87.00 price objective on shares of Enanta Pharmaceuticals in a research report on Wednesday, February 8th. JMP Securities reaffirmed a “buy” rating and issued a $96.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 22nd. JPMorgan Chase & Co. cut their price objective on shares of Enanta Pharmaceuticals from $74.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 8th. Finally, Royal Bank of Canada cut their price objective on shares of Enanta Pharmaceuticals from $65.00 to $54.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 22nd. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $68.60.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.